At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Pomaglumetad methionildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Glutamate Reducing Interventions in Schizophrenia
In Brief
A Phase 1 clinical trial evaluating Pomaglumetad methionil for Clinical High Risk for Psychosis. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to determine whether these doses of POMA are affecting glutamate levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClinical High Risk for Psychosis
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartApr 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedOct 25, 2017
Enrollment StartApr 17, 2018
Primary CompletionMar 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.7 years ago
Interventions
Pomaglumetad methionildrug
metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist